AR102545A1 - Suplementos nutricionales que contienen un componente peptídico y método de protección contra la obesidad - Google Patents

Suplementos nutricionales que contienen un componente peptídico y método de protección contra la obesidad

Info

Publication number
AR102545A1
AR102545A1 ARP150103591A ARP150103591A AR102545A1 AR 102545 A1 AR102545 A1 AR 102545A1 AR P150103591 A ARP150103591 A AR P150103591A AR P150103591 A ARP150103591 A AR P150103591A AR 102545 A1 AR102545 A1 AR 102545A1
Authority
AR
Argentina
Prior art keywords
protection against
peptide component
against obesity
nutritional supplements
supplements containing
Prior art date
Application number
ARP150103591A
Other languages
English (en)
Inventor
Kleeman Robert
Wielinga Peter
Tim Lambers Teartse
Gross Gabriele
H Schoemaker Marieke
A F Van Tol Eric
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of AR102545A1 publication Critical patent/AR102545A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)

Abstract

Un suplemento nutricional que incluye un componente peptídico. El suplemento nutricional además incluye una fuente de ácidos grasos poliinsaturados de cadena larga y Lactobacillus rhamnosus GG. Además se refiere a métodos de protección contra la obesidad y sus trastornos inflamatorios y trastornos metabólicos relacionados en un sujeto objetivo mediante la provisión del/los suplemento(s) nutricional(es) aquí descrito(s) a un sujeto objetivo, lo que incluye a un sujeto pediátrico.
ARP150103591A 2014-11-06 2015-11-05 Suplementos nutricionales que contienen un componente peptídico y método de protección contra la obesidad AR102545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/535,241 US10251928B2 (en) 2014-11-06 2014-11-06 Nutritional supplements containing a peptide component and uses thereof

Publications (1)

Publication Number Publication Date
AR102545A1 true AR102545A1 (es) 2017-03-08

Family

ID=54337903

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103591A AR102545A1 (es) 2014-11-06 2015-11-05 Suplementos nutricionales que contienen un componente peptídico y método de protección contra la obesidad

Country Status (12)

Country Link
US (3) US10251928B2 (es)
EP (1) EP3214953A1 (es)
CN (1) CN107073071A (es)
AR (1) AR102545A1 (es)
AU (1) AU2015343607A1 (es)
BR (1) BR112017008776A2 (es)
CA (1) CA2962133A1 (es)
MX (1) MX2017005776A (es)
PH (1) PH12017500740A1 (es)
SG (1) SG11201702035WA (es)
TW (1) TW201628509A (es)
WO (1) WO2016073126A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180153951A1 (en) * 2016-12-05 2018-06-07 Mead Johnson Nutrition Company Methods for Inducing Adipocyte Browning, Improving Metabolic Flexibility, and Reducing Detrimental White Adipocyte Tissue Deposition and Dysfunction
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
WO1992012711A1 (en) 1991-01-24 1992-08-06 Martek Corporation Microbial oil mixtures and uses thereof
GB9310472D0 (en) * 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
US5374567A (en) 1993-05-20 1994-12-20 The United States Of America As Represented By The Secretary Of The Navy Operational amplifier using bipolar junction transistors in silicon-on-sapphire
US6884294B2 (en) 2001-04-16 2005-04-26 Tokyo Electron Limited Coating film forming method and apparatus
US20040132819A1 (en) 2002-08-06 2004-07-08 Nancy Auestad Appetite control method
TW200412942A (en) 2002-08-06 2004-08-01 Abbott Lab Appetite control method
ATE477812T1 (de) 2003-02-07 2010-09-15 Campina Bv Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit
WO2005063050A1 (en) 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
JP2008509073A (ja) * 2004-03-01 2008-03-27 ペプテラ ファーマスーティカルズ エルティーディー． カゼイン由来ペプチドおよびその治療的使用
US20060286208A1 (en) * 2005-06-01 2006-12-21 Nagendra Rangavajla Methods for producing protein partial hydrolysates and infant formulas containing the same
US7618669B2 (en) 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
DK1898724T3 (da) 2005-07-01 2010-11-22 Nutricia Nv Spædbarnsernæring med hydrolyserede proteiner
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
BRPI0620451A2 (pt) 2005-12-23 2011-04-12 Nutricia Nv uso de uma composição compreendendo um lipìdeo, proteìna e componente de carboidrato digerìvel
EP1993530A2 (en) 2006-02-28 2008-11-26 Bristol-Myers Squibb Company Use of dha and ara in the preparation of a composition for regulating gene expression
BRPI0708378A2 (pt) 2006-02-28 2011-06-07 Bristol Myers Squibb Co uso de dha e ara na preparação de uma composição para prevenção ou tratamento de obesidade
WO2007100562A2 (en) 2006-02-28 2007-09-07 Bristol-Myers Squibb Company Use of dha and ara in the preparation of a composition for reducing triglyceride levels
US20090305945A1 (en) 2006-04-12 2009-12-10 Swen Wolfram Novel nutraceutical compositions
JP5735734B2 (ja) 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
ES2555032T3 (es) 2010-01-19 2015-12-28 Mjn U.S. Holdings Llc Compensación nutricional para dieta de tipo occidental
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en) * 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease

Also Published As

Publication number Publication date
US10933114B2 (en) 2021-03-02
SG11201702035WA (en) 2017-04-27
EP3214953A1 (en) 2017-09-13
MX2017005776A (es) 2017-07-28
US20190224273A1 (en) 2019-07-25
US20190240283A1 (en) 2019-08-08
US20160129071A1 (en) 2016-05-12
CA2962133A1 (en) 2016-05-12
US10251928B2 (en) 2019-04-09
WO2016073126A1 (en) 2016-05-12
US20210244787A9 (en) 2021-08-12
AU2015343607A1 (en) 2017-03-30
CN107073071A (zh) 2017-08-18
BR112017008776A2 (pt) 2018-05-15
TW201628509A (zh) 2016-08-16
PH12017500740A1 (en) 2017-10-09
US11077166B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
AR103260A1 (es) Modulación inmunitaria
AR100155A1 (es) Composiciones de insulina y treprostinil de rápida acción
EP3152616A4 (en) Efficient, dynamic, high contrast lensing with applications to imaging, illumination and projection
EP3294850A4 (en) Very long chain polyunsaturated fatty acids from natural oils
MX2018012056A (es) Composiciones farmaceuticas y alimenticias basadas en hafnia alvei para inducir la saciedad y prolongar la saciedad.
AR102085A1 (es) Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados
CL2016002531A1 (es) Composición de ácidos grasos monoinsaturados de cadena larga y métodos para la producción de la misma
AR105190A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
ZA202003101B (en) A dietary composition comprising plant-based sources of fatty acids
BR112016019389A8 (pt) Vacina, e, peptídeo
BR112017023636A2 (pt) suplemento dietético
IT201600078969A1 (it) Integratore alimentare
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
AR092034A1 (es) Suplemento solido para animales y metodo para elaborarlo
CO2017005911A2 (es) Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas
ZA201702977B (en) Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses.
AR102545A1 (es) Suplementos nutricionales que contienen un componente peptídico y método de protección contra la obesidad
CL2017001472A1 (es) Composiciones y métodos que comprenden triglicéridos de cadena media para el tratamiento de la epilepsia.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
BR112017012524A2 (pt) composição contendo éster parcial de carboidrato
BR112016028561A8 (pt) composição e forma de dosagem compreendendo um óleo marinho que compreende ácidos graxos, e, uso das mesmas
SG11201903370SA (en) Allulose-containing composition for promoting excretion of vegetable lipids from the body
EP3359176A4 (en) ESSENCE DE SANTAL AND USES RELATED TO ORAL MUCOSITIS
PL3250041T3 (pl) Jadalne emulsje zasadniczo wolne od kwasów tłuszczowych trans
PL3006027T3 (pl) Kompozycje zawierające aminokwasy do stosowania w leczeniu ogólnoustrojowego stanu zapalnego związanego z udarem u pacjentów z dysfagią

Legal Events

Date Code Title Description
FB Suspension of granting procedure